Switch theme
Sign up to access all valuation multiples
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
2009
28
LTM Revenue $0.8M
Last FY EBITDA -$37.7M
-$42.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Corbus Pharmaceuticals has a last 12-month revenue (LTM) of $0.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Corbus Pharmaceuticals achieved revenue of n/a and an EBITDA of -$37.7M.
Corbus Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Corbus Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$37.7M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$61.5M | XXX | -$48.7M | XXX | XXX | XXX |
| EBIT Margin | -7357% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$54.6M | XXX | -$40.2M | XXX | XXX | XXX |
| Net Margin | -6530% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Corbus Pharmaceuticals's stock price is $7.
Corbus Pharmaceuticals has current market cap of $87.6M, and EV of -$42.3M.
See Corbus Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$42.3M | $87.6M | XXX | XXX | XXX | XXX | $-4.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Corbus Pharmaceuticals has market cap of $87.6M and EV of -$42.3M.
Corbus Pharmaceuticals's trades at n/a EV/Revenue multiple, and 1.1x EV/EBITDA.
Equity research analysts estimate Corbus Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Corbus Pharmaceuticals has a P/E ratio of -1.6x.
See valuation multiples for Corbus Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $87.6M | XXX | $87.6M | XXX | XXX | XXX |
| EV (current) | -$42.3M | XXX | -$42.3M | XXX | XXX | XXX |
| EV/Revenue | -50.6x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 1.1x | XXX | XXX | XXX |
| EV/EBIT | 0.7x | XXX | 0.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.6x | XXX | -2.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCorbus Pharmaceuticals's last 12 month revenue growth is 369%
Corbus Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.7M for the same period.
Corbus Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Corbus Pharmaceuticals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Corbus Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 369% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Corbus Pharmaceuticals acquired XXX companies to date.
Last acquisition by Corbus Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Corbus Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Corbus Pharmaceuticals founded? | Corbus Pharmaceuticals was founded in 2009. |
| Where is Corbus Pharmaceuticals headquartered? | Corbus Pharmaceuticals is headquartered in United States of America. |
| How many employees does Corbus Pharmaceuticals have? | As of today, Corbus Pharmaceuticals has 28 employees. |
| Who is the CEO of Corbus Pharmaceuticals? | Corbus Pharmaceuticals's CEO is Dr. Yuval Cohen, PhD. |
| Is Corbus Pharmaceuticals publicy listed? | Yes, Corbus Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Corbus Pharmaceuticals? | Corbus Pharmaceuticals trades under CRBP ticker. |
| When did Corbus Pharmaceuticals go public? | Corbus Pharmaceuticals went public in 2014. |
| Who are competitors of Corbus Pharmaceuticals? | Similar companies to Corbus Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Corbus Pharmaceuticals? | Corbus Pharmaceuticals's current market cap is $87.6M |
| What is the current revenue of Corbus Pharmaceuticals? | Corbus Pharmaceuticals's last 12 months revenue is $0.8M. |
| What is the current revenue growth of Corbus Pharmaceuticals? | Corbus Pharmaceuticals revenue growth (NTM/LTM) is 369%. |
| What is the current EV/Revenue multiple of Corbus Pharmaceuticals? | Current revenue multiple of Corbus Pharmaceuticals is -50.6x. |
| Is Corbus Pharmaceuticals profitable? | Yes, Corbus Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
